

Witness Name: Kathleen Stewart

Statement No.: WITN1002001

Exhibits: WITN1002002 – 046

Dated: 27 September 2019

**INFECTED BLOOD INQUIRY**

---

**EXHIBIT WITN1002013**

---

Display Settings: ☒ Abstract

Full Text - FREE

BMJ Journals

Full text article  
in PubMed Central

Gut. 1981 Oct;22(10):854-9

**Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders.****Bamber M**, Murray A, Arborgh BA, Scheuer PJ, Kernoff PB, Thomas HC, Sherlock S.**Abstract**

Ten cases are reported of short incubation (one to four weeks) non-A, non-B hepatitis occurring after infusion of various preparations of factor VIII concentrates into patients with coagulation disorders. Five patients were symptomatic and, in all, serum transaminase levels were increased for at least six months. These cases of chronic hepatitis exhibited none of the features of autoimmune chronic hepatitis: autoantibodies were negative and serum immunoglobulins were normal. Hepatic histology confirmed acute hepatitis in two cases biopsied early in the illness, and chronic active hepatitis (three) of chronic persistent hepatitis (two) in five cases studied later. Lobular inflammation was a prominent feature in all cases. Other features not commonly associated with type A or B hepatitis included fatty change and damaged bile ducts.

PMID: 6795093 [PubMed - indexed for MEDLINE] PMCID: PMC1419413

Free PMC Article

**+ Publication Types, MeSH Terms, Substances****+ LinkOut - more resources**

Table 1. Patient characteristics, treatment and outcome in prospectively-studied patients

Patient	Sex	Age (yr)	Product	Batch	Dose (u/kg)	Previous exposure (donor units)	Incubation period (d)	Peak AST* (times upper limit of normal)	Symptoms*
1	M	63	Com VIII	A	860	500	10	5.3	S
2	M	53	Com VIII	B+C	670	800	9	6.3	SJ
3	F	29	Com VIII	D+E	34	190	18	2.3	SJ
4	M	77	Com VIII	F	15	300	34	8	SJ
5	M	23	Com VIII	G	11	500	35	19	()
6	F	34	Com VIII, ISG	H	781	5	36	29	SJ
7	M	21	Com VIII, ISG	I	164	200‡	20	7.4	O
8	M	19	Com VIII, ISG	I	26	1000‡	19	4.3	O
9	M	25	Com VIII, ISG	I	23	1000‡	9	39	SJ
10	M	4 mo	NHS VIII	J	300	Nil	28	2.8	O
11	M	13½	NHS VIII✓	K+L	216	200‡✓	94	10	O✓
12	M	4	NHS VIII	M	210	Nil	42	3.1	O
13	M	55	NHS VIII	N	180	200‡	65	5.7	O
14	F	10	NHS VII	O	149	35‡	58	2.5	O
15	M	8 mo	NHS VIII	P	110	Nil	48	18	O
16	M	27 mo	NHS VIII	Q	19	6	34	4.1	O
17	M	50	NHS VIII	R	16	100‡	21	24	S
18	M	42✓	NHS VIII✓	R	15	200‡✓	48	28	S✓
19	M	15✓	NHS VIII✓	S	9	200‡✓	50✓	40	SJ✓
20	F	34	NHS VIII	T	18	300	No hepatitis		
21	M	20	NHS VIII	U	8	1600	No hepatitis		
22	F	40	NHS Cryo		84	Nil	No hepatitis		
23	F	34	NHS Cryo		(70 donor units) 84	Nil	No hepatitis		
24	M	20	NHS Cryo		(70 donor units) 32	Nil	No hepatitis		
16	M	19 mo	NHS Cryo		(35 donor units) 30	Nil	No hepatitis		
25	M	6	NHS Cryo		(6 donor units) 12	Nil	No hepatitis		
26	M	19	NHS IX	a	339	20	18	24	O
27	M	16	NHS IX	b	102	Nil	26	3.8	O
28	M	22 mo	NHS IX	c+d	74	Nil	21	2.8	O
29†	M	52	NHS IX	e+f	34	Nil	7	8.5	S
30	F	38	NHS IX, ISG	g	89	10	No hepatitis		

\* S/O indicates presence/absence of symptoms, J indicates the presence of clinical jaundice.

† Patient 29 also developed hepatitis B. Details shown refer to attack of NANB hepatitis.

‡ Patients treated with blood products (cryoprecipitate exclusively) in the 6 month period before their 'first exposure' infusion.